Brief Title
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
Official Title
Phase 1 of Serum IGF II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer
Brief Summary
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical cancer.
Study Type
Observational
Condition
Cervical Cancer
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
60
Start Date
May 2011
Completion Date
September 2013
Primary Completion Date
September 2011
Eligibility Criteria
Inclusion Criteria: - Age 18 - 75 years - Female - Normal medical history - Medical history of a single type of cancer confirmed by biopsy or equivalent criteria - Squamous cell carcinoma of organs other than cervix - Adenocarcinoma - Medical history of inflammatory disease - May be pregnant - Pap smear positive for Cervical Intraepithelial Neoplasia II or III - Squamous cell cervical cancer confirmed by biopsy - Informed consent - Willingness to submit a blood sample by venipuncture - Willingness to submit a second blood sample if necessary Exclusion Criteria: - Age < 18 or > 75 years - Medical history of cancer other than cervical cancer, Non-islet-cell tumor hypoglycemia, Growth hormone deficiency, Acromegaly, Hepatoma, inflammatory disease in addition to confirmed CIN and cervical cancer
Gender
All
Ages
18 Years - 75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01371695
Organization ID
onc11-03-164
Study Sponsor
Onconix, Inc
Study Sponsor
, ,
Verification Date
June 2011